Mounjaro maker wants NHS drug price rises in return for more investment in UK
المصدر: The Guardian | Source: The GuardianUS firm Eli Lilly, which is also pushing for end to rebate scheme, optimistic about talks with ministers
The US pharmaceutical group behind the Mounjaro weight-loss drug has said it will unpause its UK investments if ministers agree to regularly increase NHS drug prices and end a rebate scheme.
Patrik Jonsson, the president of Eli Lilly’s international business, said the company was in talks with UK ministers and that he was optimistic about reaching an agreement this summer for Britain to pay more for its medicines.
Continue reading...
ملاحظة تحريرية | Editorial Note: نُشر هذا المقال في الأصل بواسطة The Guardian. خبر (Khabr) هي منصة إعلامية أردنية مرخّصة تعمل بالذكاء الاصطناعي. نضيف قيمة تحريرية من خلال: تحليل ذكي للأخبار، ملخصات تلقائية، رواية صوتية بالذكاء الاصطناعي، ترجمة متعددة اللغات، وتدقيق الحقائق. هدفنا جعل الأخبار أكثر وضوحاً وسهولةً للقارئ العربي.
This article was originally published by The Guardian. Khabr is a licensed Jordanian AI-powered news platform (Registration #82086). We add editorial value through: AI-powered news analysis, automated summaries, AI audio narration, multi-language translation (Arabic, English, French, Turkish), and AI fact-checking. Our mission is to make news more accessible and understandable for Arabic-speaking audiences worldwide.
